High circulating PCSK9 concentration is associated with increased and sex-specific risks of metabolic disease, diabetes mellitus, MASLD, and long-term mortality in a Taiwanese population. [PDF]
Lipids Health DisYeh KH, Hsu LA, Tran NY, Wu S, Ko YL.
europepmc +1 more source
Impact of mRNA and protein isoforms in lipoprotein metabolism and how to modulate them. [PDF]
Curr Opin LipidolMartinovich KM, Cale JM, Aung-Htut MT.
europepmc +1 more source
Choosing the Right Non-Statin Therapy for the Right Patient - How To Sequence Advanced Lipid-Lowering Therapies. [PDF]
Curr Atheroscler RepKatzmann JL, Laufs U.
europepmc +1 more source
Metabolic Determinants of PCSK9 Regulation in Women with Polycystic Ovary Syndrome: The Role of Insulin Resistance, Obesity, and Tobacco Smoke Exposure. [PDF]
Int J Mol SciNiepsuj J +3 more
europepmc +1 more source
Editorial: Dyslipidemia, prevention in the era of personalized medicine? [PDF]
Front Med (Lausanne)Kallel A, Banach M.
europepmc +1 more source
Serum PCSK9 is not independently associated with dyslipidaemia in type 2 diabetes: a paired cross-sectional study. [PDF]
Cardiovasc Diabetol Endocrinol RepOkoro PN +3 more
europepmc +1 more source
Lipid management: maximising reduction of cardiac risk [PDF]
, 2013 Gonna, H, Ray, KK, Webb, J
core +1 more source
Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study. [PDF]
PeerJLi Z +14 more
europepmc +1 more source
PCSK9 inhibitors: a promising lipid-lowering strategy for kidney transplant recipients. [PDF]
Ren FailLuo B, Guo L, Di W.
europepmc +1 more source